company background image
THQM

Tchaikapharma High Quality Medicines AD BUL:THQM Stock Report

Last Price

лв15.60

Market Cap

лв1.3b

7D

0.6%

1Y

9.1%

Updated

12 Aug, 2022

Data

Company Financials
THQM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

THQM Stock Overview

Tchaikapharma High Quality Medicines AD engages in the development and manufacture of generic and in-licensed medicines in Bulgaria.

Tchaikapharma High Quality Medicines AD Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tchaikapharma High Quality Medicines AD
Historical stock prices
Current Share Priceлв15.60
52 Week Highлв15.60
52 Week Lowлв13.20
Beta0.056
1 Month Change1.30%
3 Month Change1.96%
1 Year Change9.09%
3 Year Change63.64%
5 Year Change167.43%
Change since IPO523.86%

Recent News & Updates

Shareholder Returns

THQMBG PharmaceuticalsBG Market
7D0.6%-3.0%0.4%
1Y9.1%-1.0%8.8%

Return vs Industry: THQM exceeded the BG Pharmaceuticals industry which returned -1% over the past year.

Return vs Market: THQM matched the BG Market which returned 8.8% over the past year.

Price Volatility

Is THQM's price volatile compared to industry and market?
THQM volatility
THQM Average Weekly Movement1.3%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement5.2%
10% most volatile stocks in BG Market8.9%
10% least volatile stocks in BG Market2.5%

Stable Share Price: THQM is less volatile than 75% of BG stocks over the past 3 months, typically moving +/- 1% a week.

Volatility Over Time: THQM's weekly volatility (1%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999162n/ahttps://www.tchaikapharma.com

Tchaikapharma High Quality Medicines AD engages in the development and manufacture of generic and in-licensed medicines in Bulgaria. The company offers alimentary tract and metabolism, anaesthetic, antibiotic, anti-infective, cardiovascular and musculoskeletal system, nervous system, oncology, and respiratory system medicines; and solutions for injections. It also provides nutritional supplements.

Tchaikapharma High Quality Medicines AD Fundamentals Summary

How do Tchaikapharma High Quality Medicines AD's earnings and revenue compare to its market cap?
THQM fundamental statistics
Market Capлв1.32b
Earnings (TTM)лв1.54m
Revenue (TTM)лв42.98m

857.1x

P/E Ratio

30.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
THQM income statement (TTM)
Revenueлв42.98m
Cost of Revenueлв31.69m
Gross Profitлв11.30m
Other Expensesлв9.76m
Earningsлв1.54m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.018
Gross Margin26.28%
Net Profit Margin3.58%
Debt/Equity Ratio9.6%

How did THQM perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is THQM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for THQM?

Other financial metrics that can be useful for relative valuation.

THQM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue30.9x
Enterprise Value/EBITDA266.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does THQM's PS Ratio compare to its peers?

THQM PS Ratio vs Peers
The above table shows the PS ratio for THQM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.5x
SFA Sopharma AD
0.3x2.6%лв547.8m
600488 Tianjin Tianyao Pharmaceuticals
1.2xn/aCN¥4.7b
002907 Chongqing Pharscin Pharmaceutical
6.3xn/aCN¥5.1b
COLL Collegium Pharmaceutical
2.1x6.2%US$655.2m
THQM Tchaikapharma High Quality Medicines AD
30.7xn/aлв1.3b

Price-To-Sales vs Peers: THQM is expensive based on its Price-To-Sales Ratio (30.7x) compared to the peer average (2.5x).


Price to Earnings Ratio vs Industry

How does THQM's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Sales vs Industry: THQM is expensive based on its Price-To-Sales Ratio (30.7x) compared to the European Pharmaceuticals industry average (4.1x)


Price to Sales Ratio vs Fair Ratio

What is THQM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

THQM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio30.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate THQM's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of THQM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: THQM (BGN15.6) is trading above our estimate of fair value (BGN0)

Significantly Below Fair Value: THQM is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Tchaikapharma High Quality Medicines AD forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


12.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tchaikapharma High Quality Medicines AD has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has Tchaikapharma High Quality Medicines AD performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-45.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: THQM has high quality earnings.

Growing Profit Margin: THQM's current net profit margins (3.6%) are higher than last year (0.5%).


Past Earnings Growth Analysis

Earnings Trend: THQM's earnings have declined by 45.4% per year over the past 5 years.

Accelerating Growth: THQM's earnings growth over the past year (605.5%) exceeds its 5-year average (-45.4% per year).

Earnings vs Industry: THQM earnings growth over the past year (605.5%) exceeded the Pharmaceuticals industry 18.2%.


Return on Equity

High ROE: THQM's Return on Equity (1.5%) is considered low.


Discover strong past performing companies

Financial Health

How is Tchaikapharma High Quality Medicines AD's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: THQM's short term assets (BGN74.1M) exceed its short term liabilities (BGN15.6M).

Long Term Liabilities: THQM's short term assets (BGN74.1M) exceed its long term liabilities (BGN2.7M).


Debt to Equity History and Analysis

Debt Level: THQM's net debt to equity ratio (9.6%) is considered satisfactory.

Reducing Debt: THQM's debt to equity ratio has reduced from 12.8% to 9.6% over the past 5 years.

Debt Coverage: THQM's debt is well covered by operating cash flow (21.5%).

Interest Coverage: THQM earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Tchaikapharma High Quality Medicines AD current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate THQM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate THQM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if THQM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if THQM's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: THQM is not paying a notable dividend for the BG market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as THQM has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Tchaikapharma High Quality Medicines AD has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Tchaikapharma High Quality Medicines AD's employee growth, exchange listings and data sources


Key Information

  • Name: Tchaikapharma High Quality Medicines AD
  • Ticker: THQM
  • Exchange: BUL
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: лв1.318b
  • Shares outstanding: 84.50m
  • Website: https://www.tchaikapharma.com

Number of Employees


Location

  • Tchaikapharma High Quality Medicines AD
  • 1 G. M. Dimitrov Boulevard
  • Sofia
  • 1172
  • Bulgaria

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.